WallStreetZenWallStreetZen

NYSEMKT: NRXS
Neuraxis Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NRXS

Based on 1 analyst offering 12 month price targets for Neuraxis Inc

Min Forecast
$8.00+16.62%
Avg Forecast
$8.00+16.62%
Max Forecast
$8.00+16.62%

Should I buy or sell NRXS stock?

Based on 1 analyst offering ratings for Neuraxis Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NRXS's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates NRXS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their NRXS stock forecasts and price targets.

NRXS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-22

1 of 1

Forecast return on equity

Is NRXS forecast to generate an efficient return?

Company
-66.58%
Industry
16.87%
Market
150.44%
NRXS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NRXS forecast to generate an efficient return on assets?

Company
-26.34%
Industry
-4.5%
NRXS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NRXS earnings per share forecast

What is NRXS's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.57
Avg 2 year Forecast
-$0.14

NRXS revenue forecast

What is NRXS's revenue in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
$8.7M+157.86%
Avg 2 year Forecast
$19.1M+467.29%
NRXS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NRXS revenue growth forecast

How is NRXS forecast to perform vs Biotechnology companies and vs the US market?

Company
157.86%
Industry
55.55%
Market
26.27%
NRXS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NRXS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NRXS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NRXS$6.86$8.00+16.62%Buy
PTHS$24.50$54.60+122.86%Strong Buy
XBIT$2.31N/AN/A
PYPD$4.19$11.00+162.53%Strong Buy
ACET$7.21$75.00+940.22%Strong Buy
View Top Biotech Stocks

Neuraxis Stock Forecast FAQ

Is Neuraxis Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: NRXS) stock is to Buy NRXS stock.

Out of 1 analyst, 0 (0%) are recommending NRXS as a Strong Buy, 1 (100%) are recommending NRXS as a Buy, 0 (0%) are recommending NRXS as a Hold, 0 (0%) are recommending NRXS as a Sell, and 0 (0%) are recommending NRXS as a Strong Sell.

If you're new to stock investing, here's how to buy Neuraxis stock.

What is NRXS's earnings growth forecast for 2026-2027?

(NYSEMKT: NRXS) Neuraxis's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 27.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,669.5%.

Neuraxis's earnings in 2026 is -$8,370,786.On average, 4 Wall Street analysts forecast NRXS's earnings for 2026 to be -$6,030,557, with the lowest NRXS earnings forecast at -$6,055,058, and the highest NRXS earnings forecast at -$5,928,290.

In 2027, NRXS is forecast to generate -$1,521,222 in earnings, with the lowest earnings forecast at -$1,461,566 and the highest earnings forecast at -$1,565,963.

What is NRXS's revenue growth forecast for 2026-2027?

(NYSEMKT: NRXS) Neuraxis's forecast annual revenue growth rate of 157.86% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 26.27%.

Neuraxis's revenue in 2026 is $3,362,320.On average, 4 Wall Street analysts forecast NRXS's revenue for 2026 to be $92,359,880, with the lowest NRXS revenue forecast at $83,518,046, and the highest NRXS revenue forecast at $100,669,073.

In 2027, NRXS is forecast to generate $203,191,736 in revenue, with the lowest revenue forecast at $195,223,433 and the highest revenue forecast at $209,167,964.

What is NRXS's forecast return on assets (ROA) for 2026-2027?

(NYSEMKT: NRXS) forecast ROA is -26.34%, which is lower than the forecast US Biotechnology industry average of -4.5%.

What is NRXS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NRXS price target, the average NRXS price target is $8.00, with the highest NRXS stock price forecast at $8.00 and the lowest NRXS stock price forecast at $8.00.

The Wall Street analyst predicted that Neuraxis's share price could reach $8.00 by Dec 22, 2026. The average Neuraxis stock price prediction forecasts a potential upside of 16.62% from the current NRXS share price of $6.86.

What is NRXS's Earnings Per Share (EPS) forecast for 2026-2027?

(NYSEMKT: NRXS) Neuraxis's current Earnings Per Share (EPS) is -$1.00. On average, analysts forecast that NRXS's EPS will be -$0.57 for 2026, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.56. In 2027, NRXS's EPS is forecast to hit -$0.14 (min: -$0.14, max: -$0.15).

What is NRXS's forecast return on equity (ROE) for 2026-2027?

(NYSEMKT: NRXS) forecast ROE is -66.58%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.